SCHEMBL427872

SCHEMBL427872

CC1(C)COCN1C(=O)n1cnc(-c2ccccc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
GAA P10253 3/20 0.36
CYP1A2 P05177 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 2/20 0.36
GLA P06280 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CYP2C9 P11712 2/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
CNR2 P34972 5/20 0.35
GABRA5 P31644 1/20 0.35
HDAC1 Q13547 4/20 0.34
HDAC6 Q9UBN7 4/20 0.34
CYP2C19 P33261 2/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425856 0.88 CNR2 (0.39) ALDH1A1KDM4EGAAHPGDSMN1; SMN2
SCHEMBL424504 0.78 CNR2 (0.39) CNR2HDAC1HDAC6CNR1
SCHEMBL427537 0.75 GABRA5 (0.38) ALDH1A1KDM4EGAACYP1A2HPGD
SCHEMBL427876 0.74 CNR2 (0.39) ALDH1A1KDM4EGAACYP1A2HPGD
SCHEMBL427298 0.73 TSHR (0.51) ALDH1A1KDM4ECYP1A2HPGDHSD17B10
SCHEMBL427458 0.72 KDM4E (0.53) ALDH1A1KDM4EGAACYP1A2HPGD
SCHEMBL1916590 0.72 HDAC1 (0.47) ALDH1A1KDM4EGAACYP1A2HPGD
SCHEMBL11284172 0.71 NR1H2 (0.50) KDM4EGAACYP1A2HPGDHSD17B10
SCHEMBL425991 0.71 ALDH1A1 (0.40) ALDH1A1KDM4EGAACYP1A2HPGD
SCHEMBL427478 0.70 HTT (0.55) ALDH1A1KDM4EGAACYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 ALDH1A1 294/4885KDM4E 1982/4885GAA 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.